REGENXBIO/RGNX

$19.47

-2.75%
-
1D1W1MYTD1YMAX

About REGENXBIO

REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.

Ticker

RGNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kenneth Mills

Employees

401

Headquarters

Rockville, United States

REGENXBIO Metrics

BasicAdvanced
$806.81M
Market cap
-
P/E ratio
-$5.98
EPS
1.29
Beta
-
Dividend rate

What the Analysts think about REGENXBIO

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 11 analysts.
84.9% upside
High $52.00
Low $20.00
$19.47
Current price
$36.00
Average price target

REGENXBIO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-213.84% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$28.9M
45.23%
Net income
$-61.8M
-14.17%
Profit margin
-213.84%
-40.9%

REGENXBIO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 12.55%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.53
-$1.66
-$1.41
-$1.43
-
Expected
-$1.54
-$1.39
-$1.52
-$1.27
-$1.16
Surprise
-0.43%
19.86%
-7.1%
12.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell REGENXBIO stock

Buy or sell REGENXBIO stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing